| AXSOME THERAPEUT. DL-0001 |
| USA |
| Gesundheit |
| US05464T1043 / A2AA7B |
| 19X (Frankfurt) / AXSM (NASDAQ) |
| FRA:19X, ETR:19X, 19X:GR, NASDAQ:AXSM |
| - |
| https://axsome.com/ |
|
Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions wi..
>Volltext.. |
| 8184.91 Mio. EUR |
| 8095.6 Mio. EUR |
| 545.17 Mio. EUR |
| -136.86 Mio. EUR |
| -156.4 Mio. EUR |
| -3.15 EUR |
| 186.23 Mio. EUR |
| 275.73 Mio. EUR |
| -79.75 Mio. EUR |
| 0.85 |
| 45.91% |
| 43.79% |
| - |
| - |
| - |
| AXSOME |
| 30.04.26 |
|
||||
|
||||
|
||||
|